Author: Sorrentino V1, Menzies KJ2, Auwerx J1
Affiliation: <sup>1</sup>Laboratory of Integrative and Systems Physiology, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; email: admin.auwerx@epfl.ch.
<sup>2</sup>Interdisciplinary School of Health Sciences, University of Ottawa Brain and Mind Research Institute and Centre for Neuromuscular Disease, Ottawa, K1H 8M5, Canada; email: Kmenzies@uottawa.ca.
Conference/Journal: Annu Rev Pharmacol Toxicol.
Date published: 2017 Sep 27
Other:
Special Notes: doi: 10.1146/annurev-pharmtox-010716-104908. [Epub ahead of print] , Word Count: 176
Mitochondria are essential organelles for many aspects of cellular homeostasis, including energy harvesting through oxidative phosphorylation. Alterations of mitochondrial function not only impact on cellular metabolism but also critically influence whole-body metabolism, health, and life span. Diseases defined by mitochondrial dysfunction have also expanded from rare monogenic disorders in a strict sense to now also include many common polygenic diseases, including metabolic, cardiovascular, neurodegenerative, and neuromuscular diseases. This has led to an intensive search for new therapeutic and preventive strategies aimed at invigorating mitochondrial function by exploiting key components of mitochondrial biogenesis, redox metabolism, dynamics, mitophagy, and the mitochondrial unfolded protein response. As such, new findings linking mitochondrial function to the progression or outcome of this ever-increasing list of diseases has stimulated the discovery and development of the first true mitochondrial drugs, which are now entering the clinic and are discussed in this review. Expected final online publication date for the Annual Review of Pharmacology and Toxicology Volume 58 is January 6, 2018. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
PMID: 28961065 DOI: 10.1146/annurev-pharmtox-010716-104908